Hemodynamic instability after receiving intravenous perflutren for contrast echocardiography in an elderly female

Echocardiography

Volumn 21, Issue 7, 2004, Pages 613-615

  Blokh, Ilya ^a   Ganem, Amanda ^a   Bonaros, Elias P ^a   Stephen, Bibiana D ^a   Steinberg, Bart ^a   Rosen, Stacey E ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

Contrast; Echocardiography; Imaging; Microbubbles

Indexed keywords

PERFLUTREN;

AGED; ANAPHYLAXIS; ARTICLE; BACKACHE; CASE REPORT; CONTRAST ECHOCARDIOGRAPHY; DIZZINESS; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE FAILURE; HEMODYNAMICS; HOT FLUSH; HUMAN; HYPOTENSION; INJECTION PAIN; MITRAL VALVE REGURGITATION; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SWEAT GLAND DISEASE; THORAX PAIN; TRICUSPID VALVE REGURGITATION;

AGED, 80 AND OVER; ANAPHYLAXIS; CONTRAST MEDIA; ECHOCARDIOGRAPHY; ENDOCARDITIS, BACTERIAL; FEMALE; FLUOROCARBONS; HEMODYNAMIC PROCESSES; HUMANS; INFUSIONS, INTRAVENOUS; STAPHYLOCOCCAL INFECTIONS;

EID: 7044251805     PISSN: 07422822     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0742-2822.2004.03101.x     Document Type: Article

References (14)

1. Schneider, M: Design of an ultrasound contrast agent for myocardial perfusion. Echocardiography 2000;17:S11-S16.
2. Gramiak R, Shah PM: Echocardiography of the aortic root. Invest Radiol 1968;3:356-358.
3. Feinstein SB, Cheirif J, Ten FJ, et al: Safety and efficacy of a new transpulmonary ultrasound contrast agent: Initial multicenter clinical results. J Am Coll Cardiol 1990;16:316-324.
4. Kitzman DW, Goldman ME, Gillam LD, et al: Efficacy and safety of the novel ultrasound contrast agent perflutren (Definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol 2000;86:669-674.
5. Fritz T, Unger EC, Sutherland G, et al: Phase I clinical trials of MRX-115: A new ultrasound contrast agent. Invest Radiol 1997;32:735-740.
6. Grauer SE, Pantley GA, Xu J, et al: Myocardial imaging with a new transpulmonary lipid-fluorocarbon echo contrast agent: Experimental studies in pigs. Am Heart J 1996;132:938-945.
7. Grauer SE, Xu J, Pantely GA, et al: MRX 115, an echocardiographic contrast agent, produces myocardial opacification after intravenous injection in primates: Studies before and after occlusion of left anterior descending coronary artery. Acad Radiol 1996;3:S405-S406.
8. Fritz T, McKeon M, Unger E: Preclinical studies of MRX-115: Safety evaluations of a myocardial perfusion agent. Acad Radiol 1996;3:S185-S187.
9. Lindner JR, Song J, Jayaweera AR, et al: Microvascular rheology of Definity microbubbles after intraarterial and intravenous administration. J Am Soc Echocardiogr 2002;15:396-403.
10. Myreng Y, Molstad P, Ytre-Arne K, et al: Safety of the transpulmonary ultrasound contrast agent NC100100: A clinical and hemodynamic evaluation in patients with suspected and proved coronary artery disease. Heart 1999;82:333-335.
11. Morel DR, Schwieger I, Hohn L, et al: Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging. Invest Radiol 2000;35:80-85.
12. Bommer WJ, Shah PM, Allen H, et al: The safety of contrast echocardiography: Report of the Committee on Contrast Echocardiography for the American Society of Echocardiography. J Am Coll Cardiol 1984;3:6-13.
13. Kaul S: Myocardial contrast echocardiography: Basic principles. Prog Cardiovasc Dis 2001;44:1-11.
14. Sieswerda GT, Kamp O, Visser CA: Echocardiography 2000;17:S25-S36.